G2GBIO CO LTD

Location: South Korea

Nature of Business: Factory (Manufacturer and R&D Company)

Company Introduction:

G2GBIO CO LTD is a leading South Korean biotechnology company specializing in the research, development, and manufacturing of innovative long-acting injectable drug delivery systems. The company's core technology, the ATGel platform, utilizes biodegradable polymer microspheres to enable sustained release of various therapeutic agents over extended periods.

G2GBIO focuses on creating novel formulations that enhance patient convenience and adherence by reducing the frequency of injections for chronic diseases. Their product pipeline includes long-acting treatments for conditions such as prostate cancer, dementia, obesity, and diabetes. As a factory, G2GBIO is directly involved in the development, production, and quality control of its advanced pharmaceutical products.

Here are the products manufactured or sold by G2GBIO CO LTD:

* **Microparticle-based long-acting injectable platform technology**: This is their core technology used to develop sustained-release formulations.

* **G2B-IN1 (Efavirenz LA)**: A long-acting injectable formulation of Efavirenz for HIV treatment.

* **G2B-LA (Risperidone LA)**: A long-acting injectable formulation of Risperidone for schizophrenia treatment.

* **G2B-LA (Paliperidone LA)**: A long-acting injectable formulation of Paliperidone for schizophrenia treatment.

* **G2B-LA (Triptorelin LA)**: A long-acting injectable formulation of Triptorelin for prostate cancer treatment.

* **G2B-LA (Leuprolide LA)**: A long-acting injectable formulation of Leuprolide for prostate cancer treatment.

* **Others**: They also develop and manufacture other long-acting injectable products and are involved in CDMO (Contract Development and Manufacturing Organization) services.